The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

The recombinant herpes zoster vaccine (Shingrix) was not only associated with a reduced risk of herpes zoster ophthalmicus ...

After paying almost $200 to get a shingles vaccine they later learned is publicly funded, a Tillsonburg, Ont., couple says ...

Shingrix's efficacy rate is more than 90%, according to GSK. Experts recommend anyone who wants Shingrix to get on the waitlist at a pharmacy, clinic or doctor's office.

She was able to get the popular new shingles vaccine, Shingrix, at her Rite Aid pharmacy in Taylor without having to go on a waiting list. "I am a Type-2 diabetic, so it’s good for me to do the ...

Shingrix is contraindicated for immunocompromised adults with a history of severe allergies, anaphylaxis, or those with prior vaccine-related adverse reactions, according to the vaccine's label.

If you’re 50 or older, Judith Strull's story might sound familiar. Told by her doctor last month to get the new shingles vaccine, Shingrix, she went to her local CVS in Newton, Mass., expecting ...